Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|4|E60-E65

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.4, 2015-04, pp. : E60-E65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis

By  

Acta Haematologica, Vol. 133, Iss. 4, 2014-12 ,pp. : 336-346

Karger

Access to resources Recommend Favorite

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 804-813

John Wiley & Sons Inc

Access to resources Recommend Favorite

Short‐ and long‐term outcomes of AL amyloidosis patients admitted into intensive care units

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 174, Iss. 6, 2016-09 ,pp. : 868-875

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 97, Iss. 4, 2016-10 ,pp. : 342-347

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 373-377

John Wiley & Sons Inc

Access to resources Recommend Favorite